Blueprint Medicines price target lowered to $53 from $58 at Barclays

Barclays analyst Peter Lawson lowered the firm’s price target on Blueprint Medicines (BPMC) to $53 from $58 and keeps an Equal Weight rating on the shares. The analyst reduced estimates to reflect the increased competitive threat from Cogent (COGT). Following early data in systemic mastocytosis from Cogent, he sees an increased competitive threat for Blueprint.